 |
We are advised by Antengene Corporation Limited that journalists and other readers should disregard the news release, Antengene Announces XPOVIO® Approved in China for the Second-Line Treatment of Multiple Myeloma, Marking the Third Approved Indication of the Drug, issued 28-Jul-2025 over PR Newswire.
source: Antengene Corporation Limited
【你點睇？】普京稱，中俄關係是世界穩定的極重要因素，你認為中俄兩國可否通過合作在國際間釋放更大影響力？► 立即投票
